- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo matching Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 12
- States / cities
- Chula Vista, California • San Diego, California • Torrance, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 187
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Kidney Disease
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 4,304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Hawaiian Gardens, California • Lomita, California + 46 more
- Conditions
- Lupus Nephritis (LN)
- Interventions
- Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetic Kidney Disease
- Interventions
- MEDI3506, Placebo, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 42 more
- Conditions
- Chronic Kidney Disease
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 2,682,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Minneota, Minnesota
- Conditions
- Type 2 Diabetes
- Interventions
- dapagliflozin, placebo, metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 111
- States / cities
- Bayou La Batre, Alabama • Birmingham, Alabama • Huntsville, Alabama + 107 more
- Conditions
- Weight Loss
- Interventions
- Dapagliflozin Tablet, Placebo Tablet
- Drug
- Lead sponsor
- Christopher Bell
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
- Interventions
- Dapagliflozin, Placebo for Dapagliflozin, Saxagliptin, Placebo for Saxagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 905 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 48
- States / cities
- Saraland, Alabama • Fresno, California • Harbor City, California + 41 more
- Conditions
- Type II; Diabetes
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Saxagliptin, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Metformin, Glipizide 5 MG
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Heart Failure, Volume Overload
- Interventions
- Direct Sodium Removal Infusate 2.0
- Drug
- Lead sponsor
- Sequana Medical N.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy Male and Female Subjects
- Interventions
- Dapagliflozin, Metformin, Dapagliflozin + Metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Hamilton, New Jersey
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin 10 mg, Matching Placebo for Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 27
- States / cities
- Huntsville, Alabama • Burbank, California • Chula Vista, California + 22 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Glimepiride, Sitagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Heart Failure, Chronic Kidney Disease
- Interventions
- AZD9977, Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 21 Years to 130 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 26
- States / cities
- Beverly Hills, California • Fountain Valley, California • Northridge, California + 22 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 550,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 16
- States / cities
- Jonesboro, Arkansas • Fresno, California • Greenbrae, California + 13 more
- Conditions
- Chronic Kidney Disease
- Interventions
- AZD5718, Dapagliflozin 10 mg, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 22
- States / cities
- Canoga Park, California • La Mesa, California • San Carlos, California + 19 more
- Conditions
- Acute Liver Injury
- Interventions
- Not listed
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Not listed
- Enrollment
- 424,091 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Wilmington, Delaware • Washington D.C., District of Columbia
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 714,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Saxagliptin, Dapagliflozin, Placebo
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Saxagliptin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 20
- States / cities
- Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more